Tumori Journal Abstract Book - October 2020 - 191

T - Miscellanea	
Results: Cardio-Oncology documents reached 6160
downloads through the AIOM website (from 2016 to April
2020), with a trend to increase over time (550, 923, 2136
and 2046 downloads in 2016, 2017, 2018 and 2019,
respectively). On Researchgate, Cardio-Oncology documents have obtained 5146 reads up to April 2020. On the
ANMCO website, the consensus document has reached
1280 views from June 2017 to May 2020.
Conclusions: In less than 5 years, Cardio-Oncology documents published on behalf of the intersociety Working
Group have exceeded 12.000 downloads/reads/views.
These data suggest there is a need for continuing education
in Cardio-Oncology, and online medical resources created
through intersociety collaboration could help to spread
knowledge in the field.

T29
Inflammation, cancer and
prognosis: a single center
retrospective study in breast
cancer and lung cancer patients
Manca F.M.1, Lai E.1, Ziranu P.1, Impera V.2, Pretta A.2, Musio F.1,
Donisi C.1, Persano M.1, Balconi F.1, Mariani S.1, Liscia N.2, Pinna
G.1, Pireddu A.2, Madeddu C.1, Dessì M.1, Massa E.1, Atzori F.1,
Ferrari P.A.3, Cherchi R.3, Astara G.1, Scartozzi M.1
1

Medical Oncology Unit, University Hospital and University of Cagliari,
Cagliari, Italy, Cagliari; 2Medical Oncology Unit, Sapienza University of RomeUniversity Hospital and University of Cagliari, Cagliari, Italy, Cagliari; 3Division
of Thoracic Surgery, Oncological Hospital "A. Businco" - Azienda Ospedaliera
Brotzu -Cagliari, Cagliari, Italy, Cagliari

Background: The correlation between inflammation and
cancer has been extensively demonstrated in several tumour
types. Neutrophils (N)/lymphocytes (L) ratio (NLR),
platelets/L ratio (PLR), N/(L+monocytes) ratio (NLMR),
albumin, body mass index (BMI), and advanced lung cancer
inflammation index (ALI) were reported as cancer inflammation factors. We assessed their prognostic role in breast
cancer (BC) and lung cancer (LC) patients (pts).
Material (Patients) and Methods: We retrospectively
collected NLR, PLR, NLMR, albumin levels, BMI, ALI
and clinical data of LC and triple-negative (TN) and hormone positive (HR+) BC pts attending the Medical
Oncology Unit of Cagliari University Hospital and the
Division of Thoracic Surgery of Oncological Hospital "A.
Businco" - Azienda Ospedaliera Brotzu of Cagliari from
2017 to 2019. We aimed to assess the prognostic role of
these inflammation biomarkers in the study population.
Statistical analysis was performed with MedCalc package
(survival distribution: Kaplan-Meier method; survival
curves comparison: log-rank test).
Results: Globally, 92 pts were included in our analysis, 52
with BC and 40 (29 males, 11 females) with LC. In BC pts,
mean age at diagnosis was 51,8 years, 28 had TN BC (16

191
early stage, 12 stage IV) and 24 had HR+ disease (10
early stage, 14 stage IV). In LC pts, mean age at diagnosis
was 66,6 years, 20 had early stage disease amenable to surgery and 20 had stage IV cancer. Overall survival (OS)
was 85,66 months (m) (95%CI:35,9-98) in pts with
NLR⩽4.64 versus (vs) 10,33 m (95%CI:2,8-13,26) in pts
with NLR>4.64 (p<0,0001). OS was longer also with
NLMR⩽3,82 (85,66 m vs 10,33 m; 95%CI:35,9-98 and
95%CI:2,8-13,26, respectively; p<0,0001), albumin levels >3,68 g/dl (85,66 m vs 23,96 m; 95%CI:35,9-98 and
95%CI:10,33-23,96, respectively; p=0,0197), and
ALI>9,93 (85,66 m vs 10,33 m; 95%CI:35,9-98 and
95%CI:2,8-13,26, respectively; p<0,0001). Biomarkers
correlating with better prognosis were observed more frequently in BC than in LC: NLR⩽4,6 (p=0,018),
NLMR⩽3,8 (p=0,0066), albumin levels>3,68 g/dl
(p=0,0014) and ALI>9,93 (p=0,045). No differences were
observed between TN and HR+ BC pts. PLR (p=0,0495),
albumin (p<0,0001) and ALI (p=0,0183) showed significant differences between early stage and stage IV LC.
Conclusions: In our study, inflammation biomarkers
showed a negative prognostic role and were more frequent
in LC than in BC. Further studies are needed to prospectively validate their role in this population.

T30
Researchers' Pyramid - trick or
treat?
Cagnazzo C.1, Testoni S.2, Cenna R.1, Guarrera A.3, Monti M.2,
Stabile S.4, Federici I.5, Taverniti C.1, Pirondi S.6, Ferrari A.7
1
AOU Città della Salute e della Scienza, Torino; 2Istituto Scientifico
Romagnolo per lo Studio e la Cura dei Tumori, Meldola; 3AOU Careggi,
Firenze; 4Ospedale Niguarda, Milano; 5AOU ospedali Riuniti Umberto I,
Ancona; 6Ospedale di Sassuolo, Sassuolo; 7Fondazione IRCCS Policlinico San
Matteo, Pavia

Background: During the COVID-19 Coronavirus pandemic, public opinion has returned to a great deal of interest
in clinical research and the key role of researchers in periods
of health emergency. If on the one hand the emergency has
reawakened confidence in the work of researchers in the
population, on the other it has revealed leaks in the system
that insiders have known for a long time. Italian research has
always been characterized by great contradictions. While
Italy boasts the most prestigious researchers worldwide, it is
highly penalized by low investments and the inability to provide a stable career path to researchers and support staff. A
first important step to at least partially solve the problem was
the ministerial reform known as " Researchers' pyramid", an
initiative that has been the subject of strong contradictions.
Methods: In September 2019, the Italian Group of Data
Manager shared an online survey, meant for the italian biomedical research personnel, to investigate opinions about
the reform.
Tumori Journal Abstract Book - October 2020

Table of Contents for the Digital Edition of Tumori Journal Abstract Book - October 2020
